One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
What Makes hubXchange’s Roundtable Series Unique? Intimate, Senior-Level Roundtable Discussions: Engage with C-level ...
The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback